Scarica l'app Stockscreener
24.58
2.03%
-0.51
Dopo l'orario di chiusura:
24.28
-0.30
-1.22%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARQT Giù?
Forum
Previsione
Arcutis Biotherapeutics Inc Borsa (ARQT) Ultime notizie
Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026 - The Manila Times
Arcutis to give business update with Q1 results after market close May 6 - Stock Titan
Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Arcutis Biotherapeutics (ARQT) price target increased by 10.24% to 35.70 - MSN
Arcutis Biotherapeutics Targets ZORYVE Expansion, Raises 2026 Outlook and Turns Cash-Flow Positive - Yahoo Finance
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Emerges as a High-Growth Momentum Breakout Candidate - ChartMill
(ARQT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Arcutis (ARQT) announces long-term phase 3 data for ZORYVE cream in children - MSN
Is It Too Late To Revisit Arcutis Biotherapeutics (ARQT) After A 75% One-Year Surge? - Yahoo Finance
Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know - The Globe and Mail
Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know - The Motley Fool
How The Arcutis Biotherapeutics (ARQT) Story Is Evolving As Analysts Cluster Around US$35 Targets - Yahoo Finance
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales - Bitget
Aberdeen Group plc Sells 88,637 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Perpetual Ltd Sells 1,113,976 Shares of Arcutis Biotherapeutics, Inc. $ARQT - marketbeat.com
Insider Sell: Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT) - GuruFocus
Insider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) Director Sells 10,000 Shares of Stock - marketbeat.com
Planned sale: Arcutis (ARQT) director disposes of 10,000 shares - Stock Titan
Responsive Playbooks and the ARQT Inflection - Stock Traders Daily
Arcutis Biotherapeutics, Inc.Common stock (NQ: ARQT - The Chronicle-Journal
Insider sales reported at Arcutis Biotherapeutics (NASDAQ: ARQT) — two 10,000-share disposals - Stock Titan
Analysts Are Optimistic We'll See A Profit From Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Moomoo
Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference - The Manila Times
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 8.7%Here's Why - MarketBeat
Zevenbergen Capital Investments LLC Acquires Shares of 418,035 Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis executives join Needham virtual health conference April 14 - Stock Titan
Tudor Investment Corp ET AL Invests $1.32 Million in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Aug Big Picture: What are the future prospects of Arcutis Biotherapeutics Inc2026 Institutional & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Arcutis presents trial data on roflumilast cream for infants By Investing.com - Investing.com Canada
Arcutis presents trial data on roflumilast cream for infants - Investing.com
Arcutis Biotherapeutics Reports Positive Phase 2 Trial Results for ZORYVE® Cream in Infants with Atopic Dermatitis - Quiver Quantitative
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting - The Manila Times
Nearly half of infants saw eczema itch ease in 10 minutes - Stock Titan
Nordea Investment Management AB Acquires New Holdings in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
[SCHEDULE 13G/A] Arcutis Biotherapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan
Silverleafe Capital Partners LLC Increases Stock Holdings in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Understanding the Setup: (ARQT) and Scalable Risk - Stock Traders Daily
Arcutis Biotherapeutics (ARQT) Valuation Check After New Pediatric ZORYVE Phase 3 Extension Data - Yahoo Finance
A Look At Arcutis Biotherapeutics (ARQT) Valuation After Recent Share Price Weakness - simplywall.st
Arcutis (ARQT) Announces Long-Term Phase 3 Data for ZORYVE Cream in Children - Insider Monkey
Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting - Bitget
Arcutis Biotherapeutics (ARQT) Unveils New Trial Data at Dermato - GuruFocus
New eczema treatment data in infants and kids set for 2026 AAD - Stock Titan
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):